Advertisement
The reverse split has reduced the number of shares of Pharsight commonstock outstanding from approximately 28.2 million to approximately 9.4million. The exercise price and the number of shares of common stock issuableunder Pharsight's outstanding warrants and options have been proportionatelyadjusted to reflect the reverse stock split. Existing stockholders will besent instructions for exchanging existing stock certificates for new stockcertificates, and for receiving cash payments for fractional shares.
Advertisement
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products andservices that enable pharmaceutical and biotechnology companies to achievesignificant and enduring improvements in the development and use oftherapeutic products. Pharsight's goal is to help customers reduce the time,cost and risk of drug development, as well as optimize the post-approvalmarketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug developmentsuccess: strong decision-making. By adopting the Pharsight approach, customersacquire a new decision-making process with the potential to systematicallyimprove every level and phase of their business and scientific processes.Pharsight Corporation is headquartered in Mountain View, California.Information about Pharsight is available at http://www.pharsight.com.
SOURCE Pharsight Corporation
